This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
APCCC 2024
EAU 2024
SESAUA 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Renal Cancer
Conferences
Recent Abstracts
EAU 2024: Neoadjuvant Pamiparib plus Abiraterone and ADT for High-Risk/very High-Risk Localized Prostate Cancer: Results of a Prospective Study
April 7, 2024
EAU 2024: Challenging EAU Guidelines on Prostate Cancer Risk Definition in the Screening Setting: Insights from the PROBASE Trial
April 7, 2024
EAU 2024: Results from SunRISe-1 in Patients with BCG-Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 Monotherapy
April 7, 2024
EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended PLND? the Guidelines' View
April 7, 2024
EAU 2024: Results from the First Screening Round of the ProScreen Screening Trial with PSA, Kallikrein Panel and MRI
April 7, 2024
EAU 2024: Which Future for Immunotherapy in Localized Kidney Cancer?
April 7, 2024
EAU 2024: Rapid Fire Debate 6: Patient with Non-Invasive, High Grade Upper Tract Disease in Setting of Prior Radical Cystectomy – What Is Optimal Management? What If GFR ~ 50 Instead of 80?
April 7, 2024
EAU 2024: Trial in Progress: SunRISe-3: TAR-200 plus Cetrelimab or TAR-200 Versus Intravesical BCG in Patients with BCG-Naive High-Risk Non–muscle-Invasive Bladder Cancer
April 7, 2024
EAU 2024: Validation of FGFR Screening by Uromonitor® and Therascreen in FFPE Tissue in Bladder Cancer in the Context of the Clinical-Pathological Real-World Registry Study "Bladder BRIDGister"
April 7, 2024
EAU 2024: Rapid Fire Debate 5: The Age-Old Debate – What Is the Best Treatment – Oncological and QoL – for Young Healthy Patient with MIBC? What About Health Care Related Costs?
April 7, 2024
Urine Test Halves Painful Procedures in Bladder Cancer Follow Up, New Trial Shows
April 7, 2024
Five-Year Interval Is Safe for Prostate Cancer Screening, Research Shows
April 7, 2024
EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA Only - the PROBASE German Screening Trial in Young Men
April 6, 2024
EAU 2024: Development of the Bladder Utility Symptom Scale (BUSS Utility): A Novel Tool to Measure Utilities and Quality of Life in Bladder Cancer Patients
April 6, 2024
EAU 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer: PROGRxN-BCa
April 6, 2024
EAU 2024: Rapid Fire Debate 4: Patient with MIBC After Radical Cystectomy – Can We Use ctDNA to Guide Decisions on Adjuvant Chemo/IO? What About utDNA for Bladder Sparing After NAC?
April 6, 2024
EAU 2024: Towards Defining Follow-up Strategies for Patients with Primary EAU 2021 Intermediate-Risk Non-Muscle Invasive Bladder Cancer
April 6, 2024
EAU 2024: Defining Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Comparative Study of EAU and IBCG Criteria
April 6, 2024
EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: MRI Only
April 6, 2024
EAU 2024: Rapid Fire Debate 3: Healthy Patient with T1HG Micropapillary NMIBC - What Is the Best Treatment Option? What If Mixed Histologic Subtypes in Addition to Micropapillary?
April 6, 2024
Page 5 of 554
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free